{"transactions":[{"id":932310,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T21:05:12.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001637054-26-000002","document":"form4-01232026_040109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000163705426000002/form4-01232026_040109.xml","form_type":"4"}},{"id":1289535,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:35:06.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":175000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001415889-25-002486","document":"form4-01312025_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002486/form4-01312025_090101.xml","form_type":"4"}},{"id":1289534,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-01-31T21:35:06.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":83400,"source":{"system":"sec-edgar","filing":"0001415889-25-002486","document":"form4-01312025_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002486/form4-01312025_090101.xml","form_type":"4"}},{"id":1640991,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:38:54.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-24-003969","document":"form4-02152024_100242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924003969/form4-02152024_100242.xml","form_type":"4"}},{"id":2013643,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:10:23.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":2.92,"expiration_date":"2033-02-12","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-23-022383","document":"tm236831-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923022383/tm236831-1_4seq1.xml","form_type":"4"}},{"id":2388628,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-17T21:21:30.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":90000,"derivative":{"exercise_price":3.79,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-22-001518","document":"form4-02172022_010257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922001518/form4-02172022_010257.xml","form_type":"4"}},{"id":2714537,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T20:53:12.000Z","date":"2021-05-12","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":160474,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0001104659-21-065995","document":"tm2116337-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921065995/tm2116337-1_4seq1.xml","form_type":"4"}},{"id":2714536,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-05-13T20:53:12.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":351,"price":28.2044,"value":9899.7444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.12 to $28.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0001104659-21-065995","document":"tm2116337-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921065995/tm2116337-1_4seq1.xml","form_type":"4"}},{"id":2714535,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-05-13T20:53:12.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":2566,"price":27.9018,"value":71596.0188,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.095 to $28.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8751,"source":{"system":"sec-edgar","filing":"0001104659-21-065995","document":"tm2116337-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921065995/tm2116337-1_4seq1.xml","form_type":"4"}},{"id":2714534,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-05-13T20:53:12.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":1161,"price":26.106,"value":30309.066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.81 to $26.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":11317,"source":{"system":"sec-edgar","filing":"0001104659-21-065995","document":"tm2116337-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921065995/tm2116337-1_4seq1.xml","form_type":"4"}},{"id":2714533,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-05-13T20:53:12.000Z","date":"2021-05-12","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":12478,"source":{"system":"sec-edgar","filing":"0001104659-21-065995","document":"tm2116337-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921065995/tm2116337-1_4seq1.xml","form_type":"4"}},{"id":2750463,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-14T00:45:24.000Z","date":"2021-04-12","kind":"exercise","acquired":false,"shares":179915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":164552,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-21-015666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321015666/doc4.xml","form_type":"4"}},{"id":2750462,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-04-14T00:45:24.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":4078,"price":25,"value":101950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0000899243-21-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321015666/doc4.xml","form_type":"4"}},{"id":2750461,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-04-14T00:45:24.000Z","date":"2021-04-12","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":12478,"source":{"system":"sec-edgar","filing":"0000899243-21-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321015666/doc4.xml","form_type":"4"}},{"id":2786392,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-16T20:56:26.000Z","date":"2021-03-12","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":168630,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-21-011958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321011958/doc4.xml","form_type":"4"}},{"id":2786391,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-03-16T20:56:26.000Z","date":"2021-03-12","kind":"sale","acquired":false,"shares":4078,"price":26.3593,"value":107493.2254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.8375 to $26.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0000899243-21-011958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321011958/doc4.xml","form_type":"4"}},{"id":2786390,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-03-16T20:56:26.000Z","date":"2021-03-12","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":12478,"source":{"system":"sec-edgar","filing":"0000899243-21-011958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321011958/doc4.xml","form_type":"4"}},{"id":2846343,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-20T00:06:50.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":75000,"derivative":{"exercise_price":28.69,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-21-007450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321007450/doc4.xml","form_type":"4"}},{"id":2863471,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-13T02:24:21.000Z","date":"2021-02-12","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":172708,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-21-006454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321006454/doc4.xml","form_type":"4"}},{"id":2863470,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-13T02:24:21.000Z","date":"2021-02-12","kind":"sale","acquired":false,"shares":307,"price":27.6619,"value":8492.2033,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.525 to $28.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0000899243-21-006454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321006454/doc4.xml","form_type":"4"}},{"id":2863469,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-13T02:24:21.000Z","date":"2021-02-12","kind":"sale","acquired":false,"shares":3771,"price":27.1898,"value":102532.7358,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8707,"source":{"system":"sec-edgar","filing":"0000899243-21-006454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321006454/doc4.xml","form_type":"4"}},{"id":2863468,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-13T02:24:21.000Z","date":"2021-02-12","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":12478,"source":{"system":"sec-edgar","filing":"0000899243-21-006454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321006454/doc4.xml","form_type":"4"}},{"id":2907282,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to this option vested and became exercisable on December 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":71251,"derivative":{"exercise_price":10.86,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907281,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":176786,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907280,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":7511,"price":35.9999,"value":270395.2489,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.95 to $36.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907279,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":100,"price":34.125,"value":3412.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"}],"balance_after":15911,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907278,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":103,"price":32.4974,"value":3347.2322,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.495 to $32.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":16011,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907277,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":147,"price":31.9077,"value":4690.4319,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":16114,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907276,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":1669,"price":30.5043,"value":50911.6767,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.335 to $30.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":16261,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907275,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":2048,"price":29.9236,"value":61283.5328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.315 to $30.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":17930,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907274,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":7500,"price":10.86,"value":81450.0,"ownership":{"direct":true},"balance_after":19978,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2907273,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-15T01:57:25.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":12478,"source":{"system":"sec-edgar","filing":"0000899243-21-002119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321002119/doc4.xml","form_type":"4"}},{"id":2930209,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-29T21:46:20.000Z","date":"2020-12-28","kind":"exercise","acquired":false,"shares":5400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":180864,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":5400},"source":{"system":"sec-edgar","filing":"0000899243-20-035424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320035424/doc4.xml","form_type":"4"}},{"id":2930208,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-29T21:46:20.000Z","date":"2020-12-28","kind":"exercise","acquired":true,"shares":5400,"price":3.2,"value":17280.0,"ownership":{"direct":true},"balance_after":8400,"source":{"system":"sec-edgar","filing":"0000899243-20-035424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320035424/doc4.xml","form_type":"4"}},{"id":2942737,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T00:41:36.000Z","date":"2020-12-14","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":186264,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-20-034188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320034188/doc4.xml","form_type":"4"}},{"id":2942736,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-17T00:41:36.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":4078,"price":34.9491,"value":142522.4298,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.77 to $35.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-034188","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320034188/doc4.xml","form_type":"4"}},{"id":2942735,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-17T00:41:36.000Z","date":"2020-12-14","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":7078,"source":{"system":"sec-edgar","filing":"0000899243-20-034188","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320034188/doc4.xml","form_type":"4"}},{"id":2981428,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-13T21:25:57.000Z","date":"2020-11-12","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":190342,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-20-030996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030996/doc4.xml","form_type":"4"}},{"id":2981427,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-13T21:25:57.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":250,"price":35.0087,"value":8752.175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-030996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030996/doc4.xml","form_type":"4"}},{"id":2981426,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-13T21:25:57.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":2261,"price":34.2404,"value":77417.5444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.895 to $34.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3250,"source":{"system":"sec-edgar","filing":"0000899243-20-030996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030996/doc4.xml","form_type":"4"}},{"id":2981425,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-13T21:25:57.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":1567,"price":33.4632,"value":52436.8344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":5511,"source":{"system":"sec-edgar","filing":"0000899243-20-030996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030996/doc4.xml","form_type":"4"}},{"id":2981424,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-13T21:25:57.000Z","date":"2020-11-12","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":7078,"source":{"system":"sec-edgar","filing":"0000899243-20-030996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030996/doc4.xml","form_type":"4"}},{"id":3007227,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-14T20:32:13.000Z","date":"2020-10-12","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":194420,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-20-028186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320028186/doc4.xml","form_type":"4"}},{"id":3007226,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-14T20:32:13.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":295,"price":33.7541,"value":9957.4595,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-028186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320028186/doc4.xml","form_type":"4"}},{"id":3007225,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-14T20:32:13.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":3783,"price":32.6126,"value":123373.4658,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3295,"source":{"system":"sec-edgar","filing":"0000899243-20-028186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320028186/doc4.xml","form_type":"4"}},{"id":3007224,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-14T20:32:13.000Z","date":"2020-10-12","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":7078,"source":{"system":"sec-edgar","filing":"0000899243-20-028186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320028186/doc4.xml","form_type":"4"}},{"id":3030337,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-16T22:11:34.000Z","date":"2020-09-14","kind":"exercise","acquired":false,"shares":4078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":198498,"derivative":{"exercise_price":3.2,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4078},"source":{"system":"sec-edgar","filing":"0000899243-20-025361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025361/doc4.xml","form_type":"4"}},{"id":3030336,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-16T22:11:34.000Z","date":"2020-09-14","kind":"sale","acquired":false,"shares":207,"price":32.5499,"value":6737.8293,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 to $32.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-025361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025361/doc4.xml","form_type":"4"}},{"id":3030335,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-16T22:11:34.000Z","date":"2020-09-14","kind":"sale","acquired":false,"shares":1186,"price":31.4224,"value":37266.9664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $31.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3207,"source":{"system":"sec-edgar","filing":"0000899243-20-025361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025361/doc4.xml","form_type":"4"}},{"id":3030334,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-16T22:11:34.000Z","date":"2020-09-14","kind":"sale","acquired":false,"shares":2685,"price":30.7554,"value":82578.249,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":4393,"source":{"system":"sec-edgar","filing":"0000899243-20-025361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025361/doc4.xml","form_type":"4"}},{"id":3030333,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-16T22:11:34.000Z","date":"2020-09-14","kind":"exercise","acquired":true,"shares":4078,"price":3.2,"value":13049.6,"ownership":{"direct":true},"balance_after":7078,"source":{"system":"sec-edgar","filing":"0000899243-20-025361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025361/doc4.xml","form_type":"4"}},{"id":3288845,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-02-05T22:55:27.000Z","date":"2020-02-03","kind":"purchase","acquired":true,"shares":3000,"price":19,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2020, Reporting Person purchased 3,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-003354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320003354/doc4.xml","form_type":"4"}},{"id":3296749,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-31T21:50:41.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":78751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":78751,"derivative":{"exercise_price":19,"expiration_date":"2030-01-29","underlying":"Common Stock","underlying_shares":78751},"source":{"system":"sec-edgar","filing":"0000899243-20-002440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320002440/doc4.xml","form_type":"4"}},{"id":3631893,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-26T18:14:33.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly\ninstallments over the following three years, subject to continued service with RDUS through such dates."}],"balance_after":55000,"derivative":{"exercise_price":19.18,"expiration_date":"2029-02-22","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-19-013706","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119013706/doc4.xml","form_type":"4"}},{"id":3631892,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, General Counsel"}}],"security":"Common Stock","published_at":"2019-02-26T18:14:33.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates."}],"balance_after":17944,"source":{"system":"sec-edgar","filing":"0001209191-19-013706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119013706/doc4.xml","form_type":"4"}},{"id":4054649,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-15T19:42:32.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years."}],"balance_after":60000,"derivative":{"exercise_price":37.83,"expiration_date":"2028-02-12","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-18-010551","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919118010551/doc4.xml","form_type":"4"}},{"id":4165409,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, General Counsel"}}],"security":"Common Stock","published_at":"2017-11-13T07:26:44.000Z","date":"2017-11-10","kind":"purchase","acquired":true,"shares":1778,"price":28.0893,"value":49942.7754,"ownership":{"direct":true},"balance_after":2278,"source":{"system":"sec-edgar","filing":"0001209191-17-060138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919117060138/doc4.xml","form_type":"4"}},{"id":4431349,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-22T16:27:56.000Z","date":"2017-02-17","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years."}],"balance_after":60000,"derivative":{"exercise_price":45.65,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-013260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919117013260/doc4.xml","form_type":"4"}}]}